Vyome Holdings, Inc.
Vyome Holdings, Inc. operates as a healthcare firm currently in its clinical development phase, concentrating on the creation of innovative medicinal treatments designed to address both immuno-inflammatory conditions and infrequent disorders. Founded in 2017, the company extends its market reach throughout the United States and into global territories, headquartered in Princeton, New Jersey.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -0.10 | $26,955 | -$903,712 |
| 2026 Q1 | -0.17 | $31,591 | -$1M |
| 2025 Q4 | -0.21 | $36,551 | -$1M |
| 2025 Q3 | -29.42 | $34,627 | $4M |
| 2025 Q2 | -9.00 | $1M | -$4M |
| 2025 Q1 | 9.42 | $1M | -$2M |
| 2024 Q4 |
| -60.31 |
| $2M |
| -$687,000 |
| 2024 Q3 | -77.67 | $2M | -$311,000 |